Neochord
Minneapolis, Minnesota, United States · Biotechnology, Health Care, Manufacturing
NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation. The company is dedicated to advancing the treatment of mitral regurgitation and developing innovative therapies for degenerative mitral valve disease.
Key facts
- Headquarters
- Minneapolis, Minnesota, United States
- Employees
- 20
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Private
- Website
- neochord.com
- Company page
Recent activity at Neochord
- : NEOCHORD
- : NEOCHORD
- : NeoChord Appoints Todd Berg as Chief Executive Officer
- : NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation
- : NEOCHORD
- : NEOCHORD INC
- : NEOCHORD INC
- : NEOCHORD INC
- : NEOCHORD INC
- : NEOCHORD INC
Neochord funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2025 | Seed | $493K |
| Aug 2024 | Seed | $914K |
| Jul 2023 | Seed | $4.6M |
| Nov 2022 | Seed | $2.9M |
| Sep 2022 | Seed | $2.9M |
Leadership
- David Chung, Executive Officer, Director
- Mudit Jain, Director
- Andrew ElBardissi, Director
- J. Martin, Director
- Michael Liang, Director
- Casey Tansey, Director
- David Chung, Executive Officer, Director
- Mudit Jain, Director
- Andrew ElBardissi, Director
- J. Martin, Director
- Michael Liang, Director
- Casey Tansey, Director
Verified email and direct lines for Neochord’s decision-makers are on Fundz. See plans
Employee benefit plans
Neochord files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Neochord in the news
- Microinvasive mitral valve repair with transapical mitral neochordae implantation - Frontiers (Jul 27, 2023)
- Transapical off-pump mitral valve repair with NeoChord™ implantation: An early single-center Portuguese experience - www.elsevier.com (Feb 08, 2025)
- Percutaneous Mitral Valve Therapies: The Old, Current, and Future - American College of Cardiology (Jul 31, 2020)
Companies similar to Neochord
- ENDRA Life Sciences · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- QDI Systems · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Remedy Robotics · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Vishal Surgicals & Medicals · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Ontogen Medtech · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About Neochord: questions and answers
What does Neochord do?
NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation. The company is dedicated to advancing the treatment of mitral regurgitation and developing innovative therapies for degenerative mitral valve disease.
Where is Neochord headquartered?
Neochord is headquartered in Minneapolis, Minnesota, United States.
How many employees does Neochord have?
Neochord has about 20 employees.
Has Neochord raised funding?
Yes. Fundz has recorded 5 funding events for Neochord. The most recent, Seed of $493K, was in Mar 2025.
What is the latest news on Neochord?
On Mar 13, 2025, NEOCHORD
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy